Cystatin c: a Biomarker of AKI in Aneurysmal Subarachnoid Haemorrhage Patients

Alexandria University

Status

Completed

Conditions

Acute Kidney Injury

Treatments

Diagnostic Test: cystatin c

Study type

Observational

Funder types

Other

Identifiers

NCT06635408

9222704

Details and patient eligibility

About

The goal of this observational study is to assess cystatin c as a predictive biomarker of early acute kidney injury in aneurysmal subarachnoid hemorrhage patients. The main question it aims to answer is:

Does cystatin c biomarker can predict early acute kidney injury in aneurysmal subarachnoid hemorrhage patients?

Participants will be grouped into Aki and Non-Aki groups based on RIFLE criteria and Cystatin c biomarker will be tested to answer the study question.

Enrollment

52 patients

Sex

All

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Patient admission to hospital within 48 hours of subarachnoid haemorrhage onset.
Subarachnoid haemorrhage caused by intracranial aneurysm rupture and is confirmed via computed tomography angiography (CTA).
Medical treatment, microsurgical clipping, or interventional endovascular treatment of aneurysm is performed within 48 hours of subarachnoid haemorrhage onset.

Exclusion criteria

Prior onset of subarachnoid haemorrhage or other neurological diseases such as ischemic stroke, hemorrhagic stroke, or severe head trauma.
Systemic diseases, such as chronic liver diseases, chronic lung diseases, chronic heart failure, thyroid diseases and cancer.
Renal impairment at time of admission (creatinine-based eGFR less than 60 ml/min per 1.73 m2 body surface area).
Patients who are hemodynamically unstable at time of admission.
Mortality within 10 days after admission (duration of study).